Here's Why You Should Hold on to QIAGEN Stock for Now_老虎社区_美港股上老虎

Here's Why You Should Hold on to QIAGEN Stock for Now

Zacks2021-04-19

QIAGEN N.V. QGEN has been gaining on robust segmental growth and a slew of product launches. Its impressive international performance and strong revenues in the fourth quarter of 2020 buoy optimism. ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

JeffreyNeo
·2021-04-19
Hi
回复
点赞
举报
JeffreyNeo
·2021-04-19
[强]
回复
点赞
举报
JeffreyNeo
·2021-04-19
[强]
回复
点赞
举报
JeffreyNeo
·2021-04-19
[强]
回复
点赞
举报
Wallstrat
·2021-04-19
pls like and comment
回复
点赞
举报
shingshing
·2021-04-19
pls like and comment
回复
点赞
举报
收起
- Wallstrat:
  comment mine
  2021-04-19
  回复
  举报
Lammie
·2021-04-19
👍
回复
1
举报
53d72524
·2021-04-19
Hi
回复
点赞
举报
收起
- 53d72524:
  lol
  2021-04-20
  回复
  举报
WilliamTeo
·2021-04-19
Why is it
回复
1
举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2128616899?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-04-19 21:09","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2128616899","market":"us","top_or_hot":-1,"title":"Here's Why You Should Hold on to QIAGEN Stock for Now","media":"Zacks","content":"<div>\n<p>QIAGEN N.V. QGEN has been gaining on robust segmental growth and a slew of product launches. Its impressive international performance and strong revenues in the fourth quarter of 2020 buoy optimism. ...</p>\n\n<a href=\"https://finance.yahoo.com/news/heres-why-hold-qiagen-qgen-114811069.html\">网页链接</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why You Should Hold on to QIAGEN Stock for Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why You Should Hold on to QIAGEN Stock for Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-19 21:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/heres-why-hold-qiagen-qgen-114811069.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>QIAGEN N.V. QGEN has been gaining on robust segmental growth and a slew of product launches. Its impressive international performance and strong revenues in the fourth quarter of 2020 buoy optimism. ...</p>\n\n<a href=\"https://finance.yahoo.com/news/heres-why-hold-qiagen-qgen-114811069.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"QGEN","symbol_name":"快而精医药","start_time":0,"source_url":"https://finance.yahoo.com/news/heres-why-hold-qiagen-qgen-114811069.html","article_id":"2128616899","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2128616899","pubTimestamp":1618837751,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"QIAGEN N.V. QGEN has been gaining on robust segmental growth and a slew of product launches. Its imp","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"QGEN":"快而精医药","ALGN":"艾利科技"},"translate_title":"这就是为什么你现在应该持有QIAGEN的股票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALGN":0.9,"QGEN":0.9},"content_text":"QIAGEN N.V. QGEN has been gaining on robust segmental growth and a slew of product launches. Its impressive international performance and strong revenues in the fourth quarter of 2020 buoy optimism. However, downsides may result from its reliance on commercial relationships and a stiff competitive landscape.Over the past year, the Zacks Rank #3 (Hold) stock has gained 29.7% versus 1.3% fall of the industry it belongs to and 51.2% rise of the S&P 500.The renowned molecular diagnostics solutions provider has a market capitalization of $12.02 billion. The company projects 17.8% growth for the next five years and expects to maintain strong segmental performance. The company surpassed estimates in two of the trailing four quarters, missed the same in one and broke even in another, the average surprise being 1.41%.Let’s delve deeper.Product Launches: We are upbeat about QIAGEN’s recent product launches. The company, this month, announced the launch of its QIAseq DIRECT SARS-CoV-2 Kit. The kit is a viral genome enrichment and library preparation solution that significantly lessens library turnaround times and plastic use unlike the ARTIC project protocols (primer-based approaches for next-generation sequencing).The company, in March, launched QIAsphere cloud-based solutions to strengthen the scope in digital diagnostics with its syndromic testing platform, QIAstat-Dx. The same month, QIAGEN announced the launch of QIAcube Connect MDx platform for automated sample processing in molecular diagnostic laboratories, which will now be available in the United States and Canada, the European Union, and other markets globally.Collaborations to Add Value: We are optimistic about the collaborations entered into by QIAGEN over the past few months. The company extended its partnership with INOVIO Pharmaceuticals INO in February with a new master collaboration agreement to develop liquid biopsy-based companion diagnostic products based on next-generation sequencing technology to complement INOVIO’s therapies.In November 2020, QIAGEN entered into a strategic collaboration with BioNTech SE with the aim of developing and commercializing a tissue-based therascreen test as a companion diagnostic.Strong Q4 Results: QIAGEN’s robust results in the fourth quarter of 2020 instill optimism. Its revenue growth across all geographies and both operating segments in the fourth quarter was impressive. Uptick in sales for product groups used in COVID-19 response drove the top line. During the quarter, robust orders for the QIAcuity series of digital polymerase chain reaction or PCR platforms and FDA’s Emergency Use Authorization for the use of saliva samples collected with the NeuMoDx Saliva Collection Kit were also encouraging. Adjusted operating margin expansion and a raised full-year outlook were impressive as well.DownsidesReliance on Commercial Relationships: The future level of sales for companion diagnostics depends, to a high degree, on the commercial success of the related medicines for which the tests have been designed. Further, risks remain that the company may be unable to maintain these relationships and its collaborative partners may pursue or develop competing products or technologies, either on their own or in collaboration with others.Stiff Competition: QIAGEN is facing intensifying competition from firms providing pre-analytical solutions and other products used by QIAGEN’s customers. The markets for some of the company’s products are very competitive and price sensitive as well.Estimate TrendQIAGEN has been witnessing an upward estimate revision trend for 2021. Over the past 90 days, the Zacks Consensus Estimate for its earnings has moved 2% north to $2.50.The Zacks Consensus Estimate for first-quarter 2021 revenues is pegged at $555.3 million, suggesting a 49.2% rise from the year-ago reported number.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":373864620,"gmtCreate":1618839557660,"gmtModify":1634290491609,"author":{"id":"3581919031797456","authorId":"3581919031797456","name":"JeffreyNeo","avatar":"https://static.tigerbbs.com/fd016aa2ec66a904f877445461310e24","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":2,"crmLevelSwitch":0,"idStr":"3581919031797456","authorIdStr":"3581919031797456"},"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/373864620","repostId":2128616899,"repostType":4,"repost":{"id":"2128616899","pubTimestamp":1618837751,"share":"https://www.laohu8.com/m/news/2128616899?lang=&edition=full","pubTime":"2021-04-19 21:09","market":"us","language":"en","title":"Here's Why You Should Hold on to QIAGEN Stock for Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2128616899","media":"Zacks","summary":"QIAGEN N.V. QGEN has been gaining on robust segmental growth and a slew of product launches. Its imp","content":"<p><b>QIAGEN N.V.</b> QGEN has been gaining on robust segmental growth and a slew of product launches. Its impressive international performance and strong revenues in the fourth quarter of 2020 buoy optimism. However, downsides may result from its reliance on commercial relationships and a stiff competitive landscape.</p><p>Over the past year, the Zacks Rank #3 (Hold) stock has gained 29.7% versus 1.3% fall of the industry it belongs to and 51.2% rise of the S&amp;P 500.</p><p>The renowned molecular diagnostics solutions provider has a market capitalization of $12.02 billion. The company projects 17.8% growth for the next five years and expects to maintain strong segmental performance. The company surpassed estimates in two of the trailing four quarters, missed the same in <a href=\"https://laohu8.com/S/AONE\">one</a> and broke even in another, the average surprise being 1.41%.</p><p><img src=\"https://s.yimg.com/uu/api/res/1.2/wSmLPh1hcBzgFwpGTezrkw--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/zacks.com/cfa8456f1082b16b66f28fe2c2241e69\" tg-width=\"620\" tg-height=\"377\" referrerpolicy=\"no-referrer\"></p><p>Let’s delve deeper.</p><p><b>Product Launches:</b> We are upbeat about QIAGEN’s recent product launches. The company, this month, announced the launch of its QIAseq DIRECT SARS-CoV-2 Kit. The kit is a viral genome enrichment and library preparation solution that significantly lessens library turnaround times and plastic use unlike the ARTIC project protocols (primer-based approaches for next-generation sequencing).</p><p>The company, in March, launched QIAsphere cloud-based solutions to strengthen the scope in digital diagnostics with its syndromic testing platform, QIAstat-Dx. The same month, QIAGEN announced the launch of QIAcube Connect MDx platform for automated sample processing in molecular diagnostic laboratories, which will now be available in the United States and Canada, the European Union, and other markets globally.</p><p><b>Collaborations to Add Value:</b> We are optimistic about the collaborations entered into by QIAGEN over the past few months. The company extended its partnership with <b>INOVIO Pharmaceuticals</b> INO in February with a new master collaboration agreement to develop liquid biopsy-based companion diagnostic products based on next-generation sequencing technology to complement INOVIO’s therapies.</p><p>In November 2020, QIAGEN entered into a strategic collaboration with <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> with the aim of developing and commercializing a tissue-based therascreen test as a companion diagnostic.</p><p><b>Strong Q4 Results: </b>QIAGEN’s robust results in the fourth quarter of 2020 instill optimism. Its revenue growth across all geographies and both operating segments in the fourth quarter was impressive. Uptick in sales for product groups used in COVID-19 response drove the top line. During the quarter, robust orders for the QIAcuity series of digital polymerase chain reaction or PCR platforms and FDA’s Emergency Use Authorization for the use of saliva samples collected with the NeuMoDx Saliva Collection Kit were also encouraging. Adjusted operating margin expansion and a raised full-year outlook were impressive as well.</p><h3>Downsides</h3><p><b>Reliance on Commercial Relationships:</b> The future level of sales for companion diagnostics depends, to a high degree, on the commercial success of the related medicines for which the tests have been designed. Further, risks remain that the company may be unable to maintain these relationships and its collaborative partners may pursue or develop competing products or technologies, either on their own or in collaboration with others.</p><p><b>Stiff Competition: </b>QIAGEN is facing intensifying competition from firms providing pre-analytical solutions and other products used by QIAGEN’s customers. The markets for some of the company’s products are very competitive and price sensitive as well.</p><h3>Estimate Trend</h3><p>QIAGEN has been witnessing an upward estimate revision trend for 2021. Over the past 90 days, the Zacks Consensus Estimate for its earnings has moved 2% north to $2.50.</p><p>The Zacks Consensus Estimate for first-quarter 2021 revenues is pegged at $555.3 million, suggesting a 49.2% rise from the year-ago reported number.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why You Should Hold on to QIAGEN Stock for Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why You Should Hold on to QIAGEN Stock for Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-19 21:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/heres-why-hold-qiagen-qgen-114811069.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>QIAGEN N.V. QGEN has been gaining on robust segmental growth and a slew of product launches. Its impressive international performance and strong revenues in the fourth quarter of 2020 buoy optimism. ...</p>\n\n<a href=\"https://finance.yahoo.com/news/heres-why-hold-qiagen-qgen-114811069.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ALGN":"艾利科技","QGEN":"快而精医药"},"source_url":"https://finance.yahoo.com/news/heres-why-hold-qiagen-qgen-114811069.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2128616899","content_text":"QIAGEN N.V. QGEN has been gaining on robust segmental growth and a slew of product launches. Its impressive international performance and strong revenues in the fourth quarter of 2020 buoy optimism. However, downsides may result from its reliance on commercial relationships and a stiff competitive landscape.Over the past year, the Zacks Rank #3 (Hold) stock has gained 29.7% versus 1.3% fall of the industry it belongs to and 51.2% rise of the S&P 500.The renowned molecular diagnostics solutions provider has a market capitalization of $12.02 billion. The company projects 17.8% growth for the next five years and expects to maintain strong segmental performance. The company surpassed estimates in two of the trailing four quarters, missed the same in one and broke even in another, the average surprise being 1.41%.Let’s delve deeper.Product Launches: We are upbeat about QIAGEN’s recent product launches. The company, this month, announced the launch of its QIAseq DIRECT SARS-CoV-2 Kit. The kit is a viral genome enrichment and library preparation solution that significantly lessens library turnaround times and plastic use unlike the ARTIC project protocols (primer-based approaches for next-generation sequencing).The company, in March, launched QIAsphere cloud-based solutions to strengthen the scope in digital diagnostics with its syndromic testing platform, QIAstat-Dx. The same month, QIAGEN announced the launch of QIAcube Connect MDx platform for automated sample processing in molecular diagnostic laboratories, which will now be available in the United States and Canada, the European Union, and other markets globally.Collaborations to Add Value: We are optimistic about the collaborations entered into by QIAGEN over the past few months. The company extended its partnership with INOVIO Pharmaceuticals INO in February with a new master collaboration agreement to develop liquid biopsy-based companion diagnostic products based on next-generation sequencing technology to complement INOVIO’s therapies.In November 2020, QIAGEN entered into a strategic collaboration with BioNTech SE with the aim of developing and commercializing a tissue-based therascreen test as a companion diagnostic.Strong Q4 Results: QIAGEN’s robust results in the fourth quarter of 2020 instill optimism. Its revenue growth across all geographies and both operating segments in the fourth quarter was impressive. Uptick in sales for product groups used in COVID-19 response drove the top line. During the quarter, robust orders for the QIAcuity series of digital polymerase chain reaction or PCR platforms and FDA’s Emergency Use Authorization for the use of saliva samples collected with the NeuMoDx Saliva Collection Kit were also encouraging. Adjusted operating margin expansion and a raised full-year outlook were impressive as well.DownsidesReliance on Commercial Relationships: The future level of sales for companion diagnostics depends, to a high degree, on the commercial success of the related medicines for which the tests have been designed. Further, risks remain that the company may be unable to maintain these relationships and its collaborative partners may pursue or develop competing products or technologies, either on their own or in collaboration with others.Stiff Competition: QIAGEN is facing intensifying competition from firms providing pre-analytical solutions and other products used by QIAGEN’s customers. The markets for some of the company’s products are very competitive and price sensitive as well.Estimate TrendQIAGEN has been witnessing an upward estimate revision trend for 2021. Over the past 90 days, the Zacks Consensus Estimate for its earnings has moved 2% north to $2.50.The Zacks Consensus Estimate for first-quarter 2021 revenues is pegged at $555.3 million, suggesting a 49.2% rise from the year-ago reported number.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":373864367,"gmtCreate":1618839537159,"gmtModify":1634290491831,"author":{"id":"3581919031797456","authorId":"3581919031797456","name":"JeffreyNeo","avatar":"https://static.tigerbbs.com/fd016aa2ec66a904f877445461310e24","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":2,"crmLevelSwitch":0,"idStr":"3581919031797456","authorIdStr":"3581919031797456"},"htmlText":"[强]&nbsp;","listText":"[强]&nbsp;","text":"[强]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/373864367","repostId":2128616899,"repostType":4,"repost":{"id":"2128616899","pubTimestamp":1618837751,"share":"https://www.laohu8.com/m/news/2128616899?lang=&edition=full","pubTime":"2021-04-19 21:09","market":"us","language":"en","title":"Here's Why You Should Hold on to QIAGEN Stock for Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2128616899","media":"Zacks","summary":"QIAGEN N.V. QGEN has been gaining on robust segmental growth and a slew of product launches. Its imp","content":"<p><b>QIAGEN N.V.</b> QGEN has been gaining on robust segmental growth and a slew of product launches. Its impressive international performance and strong revenues in the fourth quarter of 2020 buoy optimism. However, downsides may result from its reliance on commercial relationships and a stiff competitive landscape.</p><p>Over the past year, the Zacks Rank #3 (Hold) stock has gained 29.7% versus 1.3% fall of the industry it belongs to and 51.2% rise of the S&amp;P 500.</p><p>The renowned molecular diagnostics solutions provider has a market capitalization of $12.02 billion. The company projects 17.8% growth for the next five years and expects to maintain strong segmental performance. The company surpassed estimates in two of the trailing four quarters, missed the same in <a href=\"https://laohu8.com/S/AONE\">one</a> and broke even in another, the average surprise being 1.41%.</p><p><img src=\"https://s.yimg.com/uu/api/res/1.2/wSmLPh1hcBzgFwpGTezrkw--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/zacks.com/cfa8456f1082b16b66f28fe2c2241e69\" tg-width=\"620\" tg-height=\"377\" referrerpolicy=\"no-referrer\"></p><p>Let’s delve deeper.</p><p><b>Product Launches:</b> We are upbeat about QIAGEN’s recent product launches. The company, this month, announced the launch of its QIAseq DIRECT SARS-CoV-2 Kit. The kit is a viral genome enrichment and library preparation solution that significantly lessens library turnaround times and plastic use unlike the ARTIC project protocols (primer-based approaches for next-generation sequencing).</p><p>The company, in March, launched QIAsphere cloud-based solutions to strengthen the scope in digital diagnostics with its syndromic testing platform, QIAstat-Dx. The same month, QIAGEN announced the launch of QIAcube Connect MDx platform for automated sample processing in molecular diagnostic laboratories, which will now be available in the United States and Canada, the European Union, and other markets globally.</p><p><b>Collaborations to Add Value:</b> We are optimistic about the collaborations entered into by QIAGEN over the past few months. The company extended its partnership with <b>INOVIO Pharmaceuticals</b> INO in February with a new master collaboration agreement to develop liquid biopsy-based companion diagnostic products based on next-generation sequencing technology to complement INOVIO’s therapies.</p><p>In November 2020, QIAGEN entered into a strategic collaboration with <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> with the aim of developing and commercializing a tissue-based therascreen test as a companion diagnostic.</p><p><b>Strong Q4 Results: </b>QIAGEN’s robust results in the fourth quarter of 2020 instill optimism. Its revenue growth across all geographies and both operating segments in the fourth quarter was impressive. Uptick in sales for product groups used in COVID-19 response drove the top line. During the quarter, robust orders for the QIAcuity series of digital polymerase chain reaction or PCR platforms and FDA’s Emergency Use Authorization for the use of saliva samples collected with the NeuMoDx Saliva Collection Kit were also encouraging. Adjusted operating margin expansion and a raised full-year outlook were impressive as well.</p><h3>Downsides</h3><p><b>Reliance on Commercial Relationships:</b> The future level of sales for companion diagnostics depends, to a high degree, on the commercial success of the related medicines for which the tests have been designed. Further, risks remain that the company may be unable to maintain these relationships and its collaborative partners may pursue or develop competing products or technologies, either on their own or in collaboration with others.</p><p><b>Stiff Competition: </b>QIAGEN is facing intensifying competition from firms providing pre-analytical solutions and other products used by QIAGEN’s customers. The markets for some of the company’s products are very competitive and price sensitive as well.</p><h3>Estimate Trend</h3><p>QIAGEN has been witnessing an upward estimate revision trend for 2021. Over the past 90 days, the Zacks Consensus Estimate for its earnings has moved 2% north to $2.50.</p><p>The Zacks Consensus Estimate for first-quarter 2021 revenues is pegged at $555.3 million, suggesting a 49.2% rise from the year-ago reported number.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why You Should Hold on to QIAGEN Stock for Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why You Should Hold on to QIAGEN Stock for Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-19 21:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/heres-why-hold-qiagen-qgen-114811069.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>QIAGEN N.V. QGEN has been gaining on robust segmental growth and a slew of product launches. Its impressive international performance and strong revenues in the fourth quarter of 2020 buoy optimism. ...</p>\n\n<a href=\"https://finance.yahoo.com/news/heres-why-hold-qiagen-qgen-114811069.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ALGN":"艾利科技","QGEN":"快而精医药"},"source_url":"https://finance.yahoo.com/news/heres-why-hold-qiagen-qgen-114811069.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2128616899","content_text":"QIAGEN N.V. QGEN has been gaining on robust segmental growth and a slew of product launches. Its impressive international performance and strong revenues in the fourth quarter of 2020 buoy optimism. However, downsides may result from its reliance on commercial relationships and a stiff competitive landscape.Over the past year, the Zacks Rank #3 (Hold) stock has gained 29.7% versus 1.3% fall of the industry it belongs to and 51.2% rise of the S&P 500.The renowned molecular diagnostics solutions provider has a market capitalization of $12.02 billion. The company projects 17.8% growth for the next five years and expects to maintain strong segmental performance. The company surpassed estimates in two of the trailing four quarters, missed the same in one and broke even in another, the average surprise being 1.41%.Let’s delve deeper.Product Launches: We are upbeat about QIAGEN’s recent product launches. The company, this month, announced the launch of its QIAseq DIRECT SARS-CoV-2 Kit. The kit is a viral genome enrichment and library preparation solution that significantly lessens library turnaround times and plastic use unlike the ARTIC project protocols (primer-based approaches for next-generation sequencing).The company, in March, launched QIAsphere cloud-based solutions to strengthen the scope in digital diagnostics with its syndromic testing platform, QIAstat-Dx. The same month, QIAGEN announced the launch of QIAcube Connect MDx platform for automated sample processing in molecular diagnostic laboratories, which will now be available in the United States and Canada, the European Union, and other markets globally.Collaborations to Add Value: We are optimistic about the collaborations entered into by QIAGEN over the past few months. The company extended its partnership with INOVIO Pharmaceuticals INO in February with a new master collaboration agreement to develop liquid biopsy-based companion diagnostic products based on next-generation sequencing technology to complement INOVIO’s therapies.In November 2020, QIAGEN entered into a strategic collaboration with BioNTech SE with the aim of developing and commercializing a tissue-based therascreen test as a companion diagnostic.Strong Q4 Results: QIAGEN’s robust results in the fourth quarter of 2020 instill optimism. Its revenue growth across all geographies and both operating segments in the fourth quarter was impressive. Uptick in sales for product groups used in COVID-19 response drove the top line. During the quarter, robust orders for the QIAcuity series of digital polymerase chain reaction or PCR platforms and FDA’s Emergency Use Authorization for the use of saliva samples collected with the NeuMoDx Saliva Collection Kit were also encouraging. Adjusted operating margin expansion and a raised full-year outlook were impressive as well.DownsidesReliance on Commercial Relationships: The future level of sales for companion diagnostics depends, to a high degree, on the commercial success of the related medicines for which the tests have been designed. Further, risks remain that the company may be unable to maintain these relationships and its collaborative partners may pursue or develop competing products or technologies, either on their own or in collaboration with others.Stiff Competition: QIAGEN is facing intensifying competition from firms providing pre-analytical solutions and other products used by QIAGEN’s customers. The markets for some of the company’s products are very competitive and price sensitive as well.Estimate TrendQIAGEN has been witnessing an upward estimate revision trend for 2021. Over the past 90 days, the Zacks Consensus Estimate for its earnings has moved 2% north to $2.50.The Zacks Consensus Estimate for first-quarter 2021 revenues is pegged at $555.3 million, suggesting a 49.2% rise from the year-ago reported number.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":373865949,"gmtCreate":1618839501581,"gmtModify":1634290492074,"author":{"id":"3581919031797456","authorId":"3581919031797456","name":"JeffreyNeo","avatar":"https://static.tigerbbs.com/fd016aa2ec66a904f877445461310e24","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":2,"crmLevelSwitch":0,"idStr":"3581919031797456","authorIdStr":"3581919031797456"},"htmlText":"[强]&nbsp;","listText":"[强]&nbsp;","text":"[强]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/373865949","repostId":2128616899,"repostType":4,"repost":{"id":"2128616899","pubTimestamp":1618837751,"share":"https://www.laohu8.com/m/news/2128616899?lang=&edition=full","pubTime":"2021-04-19 21:09","market":"us","language":"en","title":"Here's Why You Should Hold on to QIAGEN Stock for Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2128616899","media":"Zacks","summary":"QIAGEN N.V. QGEN has been gaining on robust segmental growth and a slew of product launches. Its imp","content":"<p><b>QIAGEN N.V.</b> QGEN has been gaining on robust segmental growth and a slew of product launches. Its impressive international performance and strong revenues in the fourth quarter of 2020 buoy optimism. However, downsides may result from its reliance on commercial relationships and a stiff competitive landscape.</p><p>Over the past year, the Zacks Rank #3 (Hold) stock has gained 29.7% versus 1.3% fall of the industry it belongs to and 51.2% rise of the S&amp;P 500.</p><p>The renowned molecular diagnostics solutions provider has a market capitalization of $12.02 billion. The company projects 17.8% growth for the next five years and expects to maintain strong segmental performance. The company surpassed estimates in two of the trailing four quarters, missed the same in <a href=\"https://laohu8.com/S/AONE\">one</a> and broke even in another, the average surprise being 1.41%.</p><p><img src=\"https://s.yimg.com/uu/api/res/1.2/wSmLPh1hcBzgFwpGTezrkw--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/zacks.com/cfa8456f1082b16b66f28fe2c2241e69\" tg-width=\"620\" tg-height=\"377\" referrerpolicy=\"no-referrer\"></p><p>Let’s delve deeper.</p><p><b>Product Launches:</b> We are upbeat about QIAGEN’s recent product launches. The company, this month, announced the launch of its QIAseq DIRECT SARS-CoV-2 Kit. The kit is a viral genome enrichment and library preparation solution that significantly lessens library turnaround times and plastic use unlike the ARTIC project protocols (primer-based approaches for next-generation sequencing).</p><p>The company, in March, launched QIAsphere cloud-based solutions to strengthen the scope in digital diagnostics with its syndromic testing platform, QIAstat-Dx. The same month, QIAGEN announced the launch of QIAcube Connect MDx platform for automated sample processing in molecular diagnostic laboratories, which will now be available in the United States and Canada, the European Union, and other markets globally.</p><p><b>Collaborations to Add Value:</b> We are optimistic about the collaborations entered into by QIAGEN over the past few months. The company extended its partnership with <b>INOVIO Pharmaceuticals</b> INO in February with a new master collaboration agreement to develop liquid biopsy-based companion diagnostic products based on next-generation sequencing technology to complement INOVIO’s therapies.</p><p>In November 2020, QIAGEN entered into a strategic collaboration with <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> with the aim of developing and commercializing a tissue-based therascreen test as a companion diagnostic.</p><p><b>Strong Q4 Results: </b>QIAGEN’s robust results in the fourth quarter of 2020 instill optimism. Its revenue growth across all geographies and both operating segments in the fourth quarter was impressive. Uptick in sales for product groups used in COVID-19 response drove the top line. During the quarter, robust orders for the QIAcuity series of digital polymerase chain reaction or PCR platforms and FDA’s Emergency Use Authorization for the use of saliva samples collected with the NeuMoDx Saliva Collection Kit were also encouraging. Adjusted operating margin expansion and a raised full-year outlook were impressive as well.</p><h3>Downsides</h3><p><b>Reliance on Commercial Relationships:</b> The future level of sales for companion diagnostics depends, to a high degree, on the commercial success of the related medicines for which the tests have been designed. Further, risks remain that the company may be unable to maintain these relationships and its collaborative partners may pursue or develop competing products or technologies, either on their own or in collaboration with others.</p><p><b>Stiff Competition: </b>QIAGEN is facing intensifying competition from firms providing pre-analytical solutions and other products used by QIAGEN’s customers. The markets for some of the company’s products are very competitive and price sensitive as well.</p><h3>Estimate Trend</h3><p>QIAGEN has been witnessing an upward estimate revision trend for 2021. Over the past 90 days, the Zacks Consensus Estimate for its earnings has moved 2% north to $2.50.</p><p>The Zacks Consensus Estimate for first-quarter 2021 revenues is pegged at $555.3 million, suggesting a 49.2% rise from the year-ago reported number.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why You Should Hold on to QIAGEN Stock for Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why You Should Hold on to QIAGEN Stock for Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-19 21:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/heres-why-hold-qiagen-qgen-114811069.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>QIAGEN N.V. QGEN has been gaining on robust segmental growth and a slew of product launches. Its impressive international performance and strong revenues in the fourth quarter of 2020 buoy optimism. ...</p>\n\n<a href=\"https://finance.yahoo.com/news/heres-why-hold-qiagen-qgen-114811069.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ALGN":"艾利科技","QGEN":"快而精医药"},"source_url":"https://finance.yahoo.com/news/heres-why-hold-qiagen-qgen-114811069.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2128616899","content_text":"QIAGEN N.V. QGEN has been gaining on robust segmental growth and a slew of product launches. Its impressive international performance and strong revenues in the fourth quarter of 2020 buoy optimism. However, downsides may result from its reliance on commercial relationships and a stiff competitive landscape.Over the past year, the Zacks Rank #3 (Hold) stock has gained 29.7% versus 1.3% fall of the industry it belongs to and 51.2% rise of the S&P 500.The renowned molecular diagnostics solutions provider has a market capitalization of $12.02 billion. The company projects 17.8% growth for the next five years and expects to maintain strong segmental performance. The company surpassed estimates in two of the trailing four quarters, missed the same in one and broke even in another, the average surprise being 1.41%.Let’s delve deeper.Product Launches: We are upbeat about QIAGEN’s recent product launches. The company, this month, announced the launch of its QIAseq DIRECT SARS-CoV-2 Kit. The kit is a viral genome enrichment and library preparation solution that significantly lessens library turnaround times and plastic use unlike the ARTIC project protocols (primer-based approaches for next-generation sequencing).The company, in March, launched QIAsphere cloud-based solutions to strengthen the scope in digital diagnostics with its syndromic testing platform, QIAstat-Dx. The same month, QIAGEN announced the launch of QIAcube Connect MDx platform for automated sample processing in molecular diagnostic laboratories, which will now be available in the United States and Canada, the European Union, and other markets globally.Collaborations to Add Value: We are optimistic about the collaborations entered into by QIAGEN over the past few months. The company extended its partnership with INOVIO Pharmaceuticals INO in February with a new master collaboration agreement to develop liquid biopsy-based companion diagnostic products based on next-generation sequencing technology to complement INOVIO’s therapies.In November 2020, QIAGEN entered into a strategic collaboration with BioNTech SE with the aim of developing and commercializing a tissue-based therascreen test as a companion diagnostic.Strong Q4 Results: QIAGEN’s robust results in the fourth quarter of 2020 instill optimism. Its revenue growth across all geographies and both operating segments in the fourth quarter was impressive. Uptick in sales for product groups used in COVID-19 response drove the top line. During the quarter, robust orders for the QIAcuity series of digital polymerase chain reaction or PCR platforms and FDA’s Emergency Use Authorization for the use of saliva samples collected with the NeuMoDx Saliva Collection Kit were also encouraging. Adjusted operating margin expansion and a raised full-year outlook were impressive as well.DownsidesReliance on Commercial Relationships: The future level of sales for companion diagnostics depends, to a high degree, on the commercial success of the related medicines for which the tests have been designed. Further, risks remain that the company may be unable to maintain these relationships and its collaborative partners may pursue or develop competing products or technologies, either on their own or in collaboration with others.Stiff Competition: QIAGEN is facing intensifying competition from firms providing pre-analytical solutions and other products used by QIAGEN’s customers. The markets for some of the company’s products are very competitive and price sensitive as well.Estimate TrendQIAGEN has been witnessing an upward estimate revision trend for 2021. Over the past 90 days, the Zacks Consensus Estimate for its earnings has moved 2% north to $2.50.The Zacks Consensus Estimate for first-quarter 2021 revenues is pegged at $555.3 million, suggesting a 49.2% rise from the year-ago reported number.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":373863463,"gmtCreate":1618839325352,"gmtModify":1634290494592,"author":{"id":"3581919031797456","authorId":"3581919031797456","name":"JeffreyNeo","avatar":"https://static.tigerbbs.com/fd016aa2ec66a904f877445461310e24","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":2,"crmLevelSwitch":0,"idStr":"3581919031797456","authorIdStr":"3581919031797456"},"htmlText":"[强]&nbsp;","listText":"[强]&nbsp;","text":"[强]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/373863463","repostId":2128616899,"repostType":4,"repost":{"id":"2128616899","pubTimestamp":1618837751,"share":"https://www.laohu8.com/m/news/2128616899?lang=&edition=full","pubTime":"2021-04-19 21:09","market":"us","language":"en","title":"Here's Why You Should Hold on to QIAGEN Stock for Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2128616899","media":"Zacks","summary":"QIAGEN N.V. QGEN has been gaining on robust segmental growth and a slew of product launches. Its imp","content":"<p><b>QIAGEN N.V.</b> QGEN has been gaining on robust segmental growth and a slew of product launches. Its impressive international performance and strong revenues in the fourth quarter of 2020 buoy optimism. However, downsides may result from its reliance on commercial relationships and a stiff competitive landscape.</p><p>Over the past year, the Zacks Rank #3 (Hold) stock has gained 29.7% versus 1.3% fall of the industry it belongs to and 51.2% rise of the S&amp;P 500.</p><p>The renowned molecular diagnostics solutions provider has a market capitalization of $12.02 billion. The company projects 17.8% growth for the next five years and expects to maintain strong segmental performance. The company surpassed estimates in two of the trailing four quarters, missed the same in <a href=\"https://laohu8.com/S/AONE\">one</a> and broke even in another, the average surprise being 1.41%.</p><p><img src=\"https://s.yimg.com/uu/api/res/1.2/wSmLPh1hcBzgFwpGTezrkw--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/zacks.com/cfa8456f1082b16b66f28fe2c2241e69\" tg-width=\"620\" tg-height=\"377\" referrerpolicy=\"no-referrer\"></p><p>Let’s delve deeper.</p><p><b>Product Launches:</b> We are upbeat about QIAGEN’s recent product launches. The company, this month, announced the launch of its QIAseq DIRECT SARS-CoV-2 Kit. The kit is a viral genome enrichment and library preparation solution that significantly lessens library turnaround times and plastic use unlike the ARTIC project protocols (primer-based approaches for next-generation sequencing).</p><p>The company, in March, launched QIAsphere cloud-based solutions to strengthen the scope in digital diagnostics with its syndromic testing platform, QIAstat-Dx. The same month, QIAGEN announced the launch of QIAcube Connect MDx platform for automated sample processing in molecular diagnostic laboratories, which will now be available in the United States and Canada, the European Union, and other markets globally.</p><p><b>Collaborations to Add Value:</b> We are optimistic about the collaborations entered into by QIAGEN over the past few months. The company extended its partnership with <b>INOVIO Pharmaceuticals</b> INO in February with a new master collaboration agreement to develop liquid biopsy-based companion diagnostic products based on next-generation sequencing technology to complement INOVIO’s therapies.</p><p>In November 2020, QIAGEN entered into a strategic collaboration with <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> with the aim of developing and commercializing a tissue-based therascreen test as a companion diagnostic.</p><p><b>Strong Q4 Results: </b>QIAGEN’s robust results in the fourth quarter of 2020 instill optimism. Its revenue growth across all geographies and both operating segments in the fourth quarter was impressive. Uptick in sales for product groups used in COVID-19 response drove the top line. During the quarter, robust orders for the QIAcuity series of digital polymerase chain reaction or PCR platforms and FDA’s Emergency Use Authorization for the use of saliva samples collected with the NeuMoDx Saliva Collection Kit were also encouraging. Adjusted operating margin expansion and a raised full-year outlook were impressive as well.</p><h3>Downsides</h3><p><b>Reliance on Commercial Relationships:</b> The future level of sales for companion diagnostics depends, to a high degree, on the commercial success of the related medicines for which the tests have been designed. Further, risks remain that the company may be unable to maintain these relationships and its collaborative partners may pursue or develop competing products or technologies, either on their own or in collaboration with others.</p><p><b>Stiff Competition: </b>QIAGEN is facing intensifying competition from firms providing pre-analytical solutions and other products used by QIAGEN’s customers. The markets for some of the company’s products are very competitive and price sensitive as well.</p><h3>Estimate Trend</h3><p>QIAGEN has been witnessing an upward estimate revision trend for 2021. Over the past 90 days, the Zacks Consensus Estimate for its earnings has moved 2% north to $2.50.</p><p>The Zacks Consensus Estimate for first-quarter 2021 revenues is pegged at $555.3 million, suggesting a 49.2% rise from the year-ago reported number.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why You Should Hold on to QIAGEN Stock for Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why You Should Hold on to QIAGEN Stock for Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-19 21:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/heres-why-hold-qiagen-qgen-114811069.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>QIAGEN N.V. QGEN has been gaining on robust segmental growth and a slew of product launches. Its impressive international performance and strong revenues in the fourth quarter of 2020 buoy optimism. ...</p>\n\n<a href=\"https://finance.yahoo.com/news/heres-why-hold-qiagen-qgen-114811069.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ALGN":"艾利科技","QGEN":"快而精医药"},"source_url":"https://finance.yahoo.com/news/heres-why-hold-qiagen-qgen-114811069.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2128616899","content_text":"QIAGEN N.V. QGEN has been gaining on robust segmental growth and a slew of product launches. Its impressive international performance and strong revenues in the fourth quarter of 2020 buoy optimism. However, downsides may result from its reliance on commercial relationships and a stiff competitive landscape.Over the past year, the Zacks Rank #3 (Hold) stock has gained 29.7% versus 1.3% fall of the industry it belongs to and 51.2% rise of the S&P 500.The renowned molecular diagnostics solutions provider has a market capitalization of $12.02 billion. The company projects 17.8% growth for the next five years and expects to maintain strong segmental performance. The company surpassed estimates in two of the trailing four quarters, missed the same in one and broke even in another, the average surprise being 1.41%.Let’s delve deeper.Product Launches: We are upbeat about QIAGEN’s recent product launches. The company, this month, announced the launch of its QIAseq DIRECT SARS-CoV-2 Kit. The kit is a viral genome enrichment and library preparation solution that significantly lessens library turnaround times and plastic use unlike the ARTIC project protocols (primer-based approaches for next-generation sequencing).The company, in March, launched QIAsphere cloud-based solutions to strengthen the scope in digital diagnostics with its syndromic testing platform, QIAstat-Dx. The same month, QIAGEN announced the launch of QIAcube Connect MDx platform for automated sample processing in molecular diagnostic laboratories, which will now be available in the United States and Canada, the European Union, and other markets globally.Collaborations to Add Value: We are optimistic about the collaborations entered into by QIAGEN over the past few months. The company extended its partnership with INOVIO Pharmaceuticals INO in February with a new master collaboration agreement to develop liquid biopsy-based companion diagnostic products based on next-generation sequencing technology to complement INOVIO’s therapies.In November 2020, QIAGEN entered into a strategic collaboration with BioNTech SE with the aim of developing and commercializing a tissue-based therascreen test as a companion diagnostic.Strong Q4 Results: QIAGEN’s robust results in the fourth quarter of 2020 instill optimism. Its revenue growth across all geographies and both operating segments in the fourth quarter was impressive. Uptick in sales for product groups used in COVID-19 response drove the top line. During the quarter, robust orders for the QIAcuity series of digital polymerase chain reaction or PCR platforms and FDA’s Emergency Use Authorization for the use of saliva samples collected with the NeuMoDx Saliva Collection Kit were also encouraging. Adjusted operating margin expansion and a raised full-year outlook were impressive as well.DownsidesReliance on Commercial Relationships: The future level of sales for companion diagnostics depends, to a high degree, on the commercial success of the related medicines for which the tests have been designed. Further, risks remain that the company may be unable to maintain these relationships and its collaborative partners may pursue or develop competing products or technologies, either on their own or in collaboration with others.Stiff Competition: QIAGEN is facing intensifying competition from firms providing pre-analytical solutions and other products used by QIAGEN’s customers. The markets for some of the company’s products are very competitive and price sensitive as well.Estimate TrendQIAGEN has been witnessing an upward estimate revision trend for 2021. Over the past 90 days, the Zacks Consensus Estimate for its earnings has moved 2% north to $2.50.The Zacks Consensus Estimate for first-quarter 2021 revenues is pegged at $555.3 million, suggesting a 49.2% rise from the year-ago reported number.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":373817254,"gmtCreate":1618838688478,"gmtModify":1634290503636,"author":{"id":"3577594477850307","authorId":"3577594477850307","name":"Wallstrat","avatar":"https://static.tigerbbs.com/72e278e5cb2ede803b1dff8ad9415a5c","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3577594477850307","authorIdStr":"3577594477850307"},"htmlText":"pls like and comment","listText":"pls like and comment","text":"pls like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/373817254","repostId":2128616899,"repostType":4,"repost":{"id":"2128616899","pubTimestamp":1618837751,"share":"https://www.laohu8.com/m/news/2128616899?lang=&edition=full","pubTime":"2021-04-19 21:09","market":"us","language":"en","title":"Here's Why You Should Hold on to QIAGEN Stock for Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2128616899","media":"Zacks","summary":"QIAGEN N.V. QGEN has been gaining on robust segmental growth and a slew of product launches. Its imp","content":"<p><b>QIAGEN N.V.</b> QGEN has been gaining on robust segmental growth and a slew of product launches. Its impressive international performance and strong revenues in the fourth quarter of 2020 buoy optimism. However, downsides may result from its reliance on commercial relationships and a stiff competitive landscape.</p><p>Over the past year, the Zacks Rank #3 (Hold) stock has gained 29.7% versus 1.3% fall of the industry it belongs to and 51.2% rise of the S&amp;P 500.</p><p>The renowned molecular diagnostics solutions provider has a market capitalization of $12.02 billion. The company projects 17.8% growth for the next five years and expects to maintain strong segmental performance. The company surpassed estimates in two of the trailing four quarters, missed the same in <a href=\"https://laohu8.com/S/AONE\">one</a> and broke even in another, the average surprise being 1.41%.</p><p><img src=\"https://s.yimg.com/uu/api/res/1.2/wSmLPh1hcBzgFwpGTezrkw--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/zacks.com/cfa8456f1082b16b66f28fe2c2241e69\" tg-width=\"620\" tg-height=\"377\" referrerpolicy=\"no-referrer\"></p><p>Let’s delve deeper.</p><p><b>Product Launches:</b> We are upbeat about QIAGEN’s recent product launches. The company, this month, announced the launch of its QIAseq DIRECT SARS-CoV-2 Kit. The kit is a viral genome enrichment and library preparation solution that significantly lessens library turnaround times and plastic use unlike the ARTIC project protocols (primer-based approaches for next-generation sequencing).</p><p>The company, in March, launched QIAsphere cloud-based solutions to strengthen the scope in digital diagnostics with its syndromic testing platform, QIAstat-Dx. The same month, QIAGEN announced the launch of QIAcube Connect MDx platform for automated sample processing in molecular diagnostic laboratories, which will now be available in the United States and Canada, the European Union, and other markets globally.</p><p><b>Collaborations to Add Value:</b> We are optimistic about the collaborations entered into by QIAGEN over the past few months. The company extended its partnership with <b>INOVIO Pharmaceuticals</b> INO in February with a new master collaboration agreement to develop liquid biopsy-based companion diagnostic products based on next-generation sequencing technology to complement INOVIO’s therapies.</p><p>In November 2020, QIAGEN entered into a strategic collaboration with <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> with the aim of developing and commercializing a tissue-based therascreen test as a companion diagnostic.</p><p><b>Strong Q4 Results: </b>QIAGEN’s robust results in the fourth quarter of 2020 instill optimism. Its revenue growth across all geographies and both operating segments in the fourth quarter was impressive. Uptick in sales for product groups used in COVID-19 response drove the top line. During the quarter, robust orders for the QIAcuity series of digital polymerase chain reaction or PCR platforms and FDA’s Emergency Use Authorization for the use of saliva samples collected with the NeuMoDx Saliva Collection Kit were also encouraging. Adjusted operating margin expansion and a raised full-year outlook were impressive as well.</p><h3>Downsides</h3><p><b>Reliance on Commercial Relationships:</b> The future level of sales for companion diagnostics depends, to a high degree, on the commercial success of the related medicines for which the tests have been designed. Further, risks remain that the company may be unable to maintain these relationships and its collaborative partners may pursue or develop competing products or technologies, either on their own or in collaboration with others.</p><p><b>Stiff Competition: </b>QIAGEN is facing intensifying competition from firms providing pre-analytical solutions and other products used by QIAGEN’s customers. The markets for some of the company’s products are very competitive and price sensitive as well.</p><h3>Estimate Trend</h3><p>QIAGEN has been witnessing an upward estimate revision trend for 2021. Over the past 90 days, the Zacks Consensus Estimate for its earnings has moved 2% north to $2.50.</p><p>The Zacks Consensus Estimate for first-quarter 2021 revenues is pegged at $555.3 million, suggesting a 49.2% rise from the year-ago reported number.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why You Should Hold on to QIAGEN Stock for Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why You Should Hold on to QIAGEN Stock for Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-19 21:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/heres-why-hold-qiagen-qgen-114811069.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>QIAGEN N.V. QGEN has been gaining on robust segmental growth and a slew of product launches. Its impressive international performance and strong revenues in the fourth quarter of 2020 buoy optimism. ...</p>\n\n<a href=\"https://finance.yahoo.com/news/heres-why-hold-qiagen-qgen-114811069.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ALGN":"艾利科技","QGEN":"快而精医药"},"source_url":"https://finance.yahoo.com/news/heres-why-hold-qiagen-qgen-114811069.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2128616899","content_text":"QIAGEN N.V. QGEN has been gaining on robust segmental growth and a slew of product launches. Its impressive international performance and strong revenues in the fourth quarter of 2020 buoy optimism. However, downsides may result from its reliance on commercial relationships and a stiff competitive landscape.Over the past year, the Zacks Rank #3 (Hold) stock has gained 29.7% versus 1.3% fall of the industry it belongs to and 51.2% rise of the S&P 500.The renowned molecular diagnostics solutions provider has a market capitalization of $12.02 billion. The company projects 17.8% growth for the next five years and expects to maintain strong segmental performance. The company surpassed estimates in two of the trailing four quarters, missed the same in one and broke even in another, the average surprise being 1.41%.Let’s delve deeper.Product Launches: We are upbeat about QIAGEN’s recent product launches. The company, this month, announced the launch of its QIAseq DIRECT SARS-CoV-2 Kit. The kit is a viral genome enrichment and library preparation solution that significantly lessens library turnaround times and plastic use unlike the ARTIC project protocols (primer-based approaches for next-generation sequencing).The company, in March, launched QIAsphere cloud-based solutions to strengthen the scope in digital diagnostics with its syndromic testing platform, QIAstat-Dx. The same month, QIAGEN announced the launch of QIAcube Connect MDx platform for automated sample processing in molecular diagnostic laboratories, which will now be available in the United States and Canada, the European Union, and other markets globally.Collaborations to Add Value: We are optimistic about the collaborations entered into by QIAGEN over the past few months. The company extended its partnership with INOVIO Pharmaceuticals INO in February with a new master collaboration agreement to develop liquid biopsy-based companion diagnostic products based on next-generation sequencing technology to complement INOVIO’s therapies.In November 2020, QIAGEN entered into a strategic collaboration with BioNTech SE with the aim of developing and commercializing a tissue-based therascreen test as a companion diagnostic.Strong Q4 Results: QIAGEN’s robust results in the fourth quarter of 2020 instill optimism. Its revenue growth across all geographies and both operating segments in the fourth quarter was impressive. Uptick in sales for product groups used in COVID-19 response drove the top line. During the quarter, robust orders for the QIAcuity series of digital polymerase chain reaction or PCR platforms and FDA’s Emergency Use Authorization for the use of saliva samples collected with the NeuMoDx Saliva Collection Kit were also encouraging. Adjusted operating margin expansion and a raised full-year outlook were impressive as well.DownsidesReliance on Commercial Relationships: The future level of sales for companion diagnostics depends, to a high degree, on the commercial success of the related medicines for which the tests have been designed. Further, risks remain that the company may be unable to maintain these relationships and its collaborative partners may pursue or develop competing products or technologies, either on their own or in collaboration with others.Stiff Competition: QIAGEN is facing intensifying competition from firms providing pre-analytical solutions and other products used by QIAGEN’s customers. The markets for some of the company’s products are very competitive and price sensitive as well.Estimate TrendQIAGEN has been witnessing an upward estimate revision trend for 2021. Over the past 90 days, the Zacks Consensus Estimate for its earnings has moved 2% north to $2.50.The Zacks Consensus Estimate for first-quarter 2021 revenues is pegged at $555.3 million, suggesting a 49.2% rise from the year-ago reported number.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":373812430,"gmtCreate":1618838538620,"gmtModify":1634290505382,"author":{"id":"3575272090049472","authorId":"3575272090049472","name":"shingshing","avatar":"https://static.tigerbbs.com/d263f89b8d7eb0e2f50ca6bd55e3cab2","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3575272090049472","authorIdStr":"3575272090049472"},"htmlText":"pls like and comment","listText":"pls like and comment","text":"pls like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/373812430","repostId":2128616899,"repostType":4,"repost":{"id":"2128616899","pubTimestamp":1618837751,"share":"https://www.laohu8.com/m/news/2128616899?lang=&edition=full","pubTime":"2021-04-19 21:09","market":"us","language":"en","title":"Here's Why You Should Hold on to QIAGEN Stock for Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2128616899","media":"Zacks","summary":"QIAGEN N.V. QGEN has been gaining on robust segmental growth and a slew of product launches. Its imp","content":"<p><b>QIAGEN N.V.</b> QGEN has been gaining on robust segmental growth and a slew of product launches. Its impressive international performance and strong revenues in the fourth quarter of 2020 buoy optimism. However, downsides may result from its reliance on commercial relationships and a stiff competitive landscape.</p><p>Over the past year, the Zacks Rank #3 (Hold) stock has gained 29.7% versus 1.3% fall of the industry it belongs to and 51.2% rise of the S&amp;P 500.</p><p>The renowned molecular diagnostics solutions provider has a market capitalization of $12.02 billion. The company projects 17.8% growth for the next five years and expects to maintain strong segmental performance. The company surpassed estimates in two of the trailing four quarters, missed the same in <a href=\"https://laohu8.com/S/AONE\">one</a> and broke even in another, the average surprise being 1.41%.</p><p><img src=\"https://s.yimg.com/uu/api/res/1.2/wSmLPh1hcBzgFwpGTezrkw--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/zacks.com/cfa8456f1082b16b66f28fe2c2241e69\" tg-width=\"620\" tg-height=\"377\" referrerpolicy=\"no-referrer\"></p><p>Let’s delve deeper.</p><p><b>Product Launches:</b> We are upbeat about QIAGEN’s recent product launches. The company, this month, announced the launch of its QIAseq DIRECT SARS-CoV-2 Kit. The kit is a viral genome enrichment and library preparation solution that significantly lessens library turnaround times and plastic use unlike the ARTIC project protocols (primer-based approaches for next-generation sequencing).</p><p>The company, in March, launched QIAsphere cloud-based solutions to strengthen the scope in digital diagnostics with its syndromic testing platform, QIAstat-Dx. The same month, QIAGEN announced the launch of QIAcube Connect MDx platform for automated sample processing in molecular diagnostic laboratories, which will now be available in the United States and Canada, the European Union, and other markets globally.</p><p><b>Collaborations to Add Value:</b> We are optimistic about the collaborations entered into by QIAGEN over the past few months. The company extended its partnership with <b>INOVIO Pharmaceuticals</b> INO in February with a new master collaboration agreement to develop liquid biopsy-based companion diagnostic products based on next-generation sequencing technology to complement INOVIO’s therapies.</p><p>In November 2020, QIAGEN entered into a strategic collaboration with <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> with the aim of developing and commercializing a tissue-based therascreen test as a companion diagnostic.</p><p><b>Strong Q4 Results: </b>QIAGEN’s robust results in the fourth quarter of 2020 instill optimism. Its revenue growth across all geographies and both operating segments in the fourth quarter was impressive. Uptick in sales for product groups used in COVID-19 response drove the top line. During the quarter, robust orders for the QIAcuity series of digital polymerase chain reaction or PCR platforms and FDA’s Emergency Use Authorization for the use of saliva samples collected with the NeuMoDx Saliva Collection Kit were also encouraging. Adjusted operating margin expansion and a raised full-year outlook were impressive as well.</p><h3>Downsides</h3><p><b>Reliance on Commercial Relationships:</b> The future level of sales for companion diagnostics depends, to a high degree, on the commercial success of the related medicines for which the tests have been designed. Further, risks remain that the company may be unable to maintain these relationships and its collaborative partners may pursue or develop competing products or technologies, either on their own or in collaboration with others.</p><p><b>Stiff Competition: </b>QIAGEN is facing intensifying competition from firms providing pre-analytical solutions and other products used by QIAGEN’s customers. The markets for some of the company’s products are very competitive and price sensitive as well.</p><h3>Estimate Trend</h3><p>QIAGEN has been witnessing an upward estimate revision trend for 2021. Over the past 90 days, the Zacks Consensus Estimate for its earnings has moved 2% north to $2.50.</p><p>The Zacks Consensus Estimate for first-quarter 2021 revenues is pegged at $555.3 million, suggesting a 49.2% rise from the year-ago reported number.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why You Should Hold on to QIAGEN Stock for Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why You Should Hold on to QIAGEN Stock for Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-19 21:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/heres-why-hold-qiagen-qgen-114811069.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>QIAGEN N.V. QGEN has been gaining on robust segmental growth and a slew of product launches. Its impressive international performance and strong revenues in the fourth quarter of 2020 buoy optimism. ...</p>\n\n<a href=\"https://finance.yahoo.com/news/heres-why-hold-qiagen-qgen-114811069.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ALGN":"艾利科技","QGEN":"快而精医药"},"source_url":"https://finance.yahoo.com/news/heres-why-hold-qiagen-qgen-114811069.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2128616899","content_text":"QIAGEN N.V. QGEN has been gaining on robust segmental growth and a slew of product launches. Its impressive international performance and strong revenues in the fourth quarter of 2020 buoy optimism. However, downsides may result from its reliance on commercial relationships and a stiff competitive landscape.Over the past year, the Zacks Rank #3 (Hold) stock has gained 29.7% versus 1.3% fall of the industry it belongs to and 51.2% rise of the S&P 500.The renowned molecular diagnostics solutions provider has a market capitalization of $12.02 billion. The company projects 17.8% growth for the next five years and expects to maintain strong segmental performance. The company surpassed estimates in two of the trailing four quarters, missed the same in one and broke even in another, the average surprise being 1.41%.Let’s delve deeper.Product Launches: We are upbeat about QIAGEN’s recent product launches. The company, this month, announced the launch of its QIAseq DIRECT SARS-CoV-2 Kit. The kit is a viral genome enrichment and library preparation solution that significantly lessens library turnaround times and plastic use unlike the ARTIC project protocols (primer-based approaches for next-generation sequencing).The company, in March, launched QIAsphere cloud-based solutions to strengthen the scope in digital diagnostics with its syndromic testing platform, QIAstat-Dx. The same month, QIAGEN announced the launch of QIAcube Connect MDx platform for automated sample processing in molecular diagnostic laboratories, which will now be available in the United States and Canada, the European Union, and other markets globally.Collaborations to Add Value: We are optimistic about the collaborations entered into by QIAGEN over the past few months. The company extended its partnership with INOVIO Pharmaceuticals INO in February with a new master collaboration agreement to develop liquid biopsy-based companion diagnostic products based on next-generation sequencing technology to complement INOVIO’s therapies.In November 2020, QIAGEN entered into a strategic collaboration with BioNTech SE with the aim of developing and commercializing a tissue-based therascreen test as a companion diagnostic.Strong Q4 Results: QIAGEN’s robust results in the fourth quarter of 2020 instill optimism. Its revenue growth across all geographies and both operating segments in the fourth quarter was impressive. Uptick in sales for product groups used in COVID-19 response drove the top line. During the quarter, robust orders for the QIAcuity series of digital polymerase chain reaction or PCR platforms and FDA’s Emergency Use Authorization for the use of saliva samples collected with the NeuMoDx Saliva Collection Kit were also encouraging. Adjusted operating margin expansion and a raised full-year outlook were impressive as well.DownsidesReliance on Commercial Relationships: The future level of sales for companion diagnostics depends, to a high degree, on the commercial success of the related medicines for which the tests have been designed. Further, risks remain that the company may be unable to maintain these relationships and its collaborative partners may pursue or develop competing products or technologies, either on their own or in collaboration with others.Stiff Competition: QIAGEN is facing intensifying competition from firms providing pre-analytical solutions and other products used by QIAGEN’s customers. The markets for some of the company’s products are very competitive and price sensitive as well.Estimate TrendQIAGEN has been witnessing an upward estimate revision trend for 2021. Over the past 90 days, the Zacks Consensus Estimate for its earnings has moved 2% north to $2.50.The Zacks Consensus Estimate for first-quarter 2021 revenues is pegged at $555.3 million, suggesting a 49.2% rise from the year-ago reported number.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4074568,"gmtCreate":1618838707951,"gmtModify":1635516213450,"authorId":3577594477850307,"author":{"id":3577594477850307,"idStr":"3577594477850307","authorId":3577594477850307,"name":"Wallstrat","avatar":"https://static.tigerbbs.com/72e278e5cb2ede803b1dff8ad9415a5c","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":373812430,"type":1,"supId":0,"prevId":0,"content":"comment mine","text":"comment mine","html":"comment mine"}],"langContent":"EN"},{"id":373813736,"gmtCreate":1618838254825,"gmtModify":1634290508337,"author":{"id":"3579863048316157","authorId":"3579863048316157","name":"Lammie","avatar":"https://static.tigerbbs.com/22f853e264a96287b9819a7a9d2d2f84","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3579863048316157","authorIdStr":"3579863048316157"},"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/373813736","repostId":2128616899,"repostType":4,"repost":{"id":"2128616899","pubTimestamp":1618837751,"share":"https://www.laohu8.com/m/news/2128616899?lang=&edition=full","pubTime":"2021-04-19 21:09","market":"us","language":"en","title":"Here's Why You Should Hold on to QIAGEN Stock for Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2128616899","media":"Zacks","summary":"QIAGEN N.V. QGEN has been gaining on robust segmental growth and a slew of product launches. Its imp","content":"<p><b>QIAGEN N.V.</b> QGEN has been gaining on robust segmental growth and a slew of product launches. Its impressive international performance and strong revenues in the fourth quarter of 2020 buoy optimism. However, downsides may result from its reliance on commercial relationships and a stiff competitive landscape.</p><p>Over the past year, the Zacks Rank #3 (Hold) stock has gained 29.7% versus 1.3% fall of the industry it belongs to and 51.2% rise of the S&amp;P 500.</p><p>The renowned molecular diagnostics solutions provider has a market capitalization of $12.02 billion. The company projects 17.8% growth for the next five years and expects to maintain strong segmental performance. The company surpassed estimates in two of the trailing four quarters, missed the same in <a href=\"https://laohu8.com/S/AONE\">one</a> and broke even in another, the average surprise being 1.41%.</p><p><img src=\"https://s.yimg.com/uu/api/res/1.2/wSmLPh1hcBzgFwpGTezrkw--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/zacks.com/cfa8456f1082b16b66f28fe2c2241e69\" tg-width=\"620\" tg-height=\"377\" referrerpolicy=\"no-referrer\"></p><p>Let’s delve deeper.</p><p><b>Product Launches:</b> We are upbeat about QIAGEN’s recent product launches. The company, this month, announced the launch of its QIAseq DIRECT SARS-CoV-2 Kit. The kit is a viral genome enrichment and library preparation solution that significantly lessens library turnaround times and plastic use unlike the ARTIC project protocols (primer-based approaches for next-generation sequencing).</p><p>The company, in March, launched QIAsphere cloud-based solutions to strengthen the scope in digital diagnostics with its syndromic testing platform, QIAstat-Dx. The same month, QIAGEN announced the launch of QIAcube Connect MDx platform for automated sample processing in molecular diagnostic laboratories, which will now be available in the United States and Canada, the European Union, and other markets globally.</p><p><b>Collaborations to Add Value:</b> We are optimistic about the collaborations entered into by QIAGEN over the past few months. The company extended its partnership with <b>INOVIO Pharmaceuticals</b> INO in February with a new master collaboration agreement to develop liquid biopsy-based companion diagnostic products based on next-generation sequencing technology to complement INOVIO’s therapies.</p><p>In November 2020, QIAGEN entered into a strategic collaboration with <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> with the aim of developing and commercializing a tissue-based therascreen test as a companion diagnostic.</p><p><b>Strong Q4 Results: </b>QIAGEN’s robust results in the fourth quarter of 2020 instill optimism. Its revenue growth across all geographies and both operating segments in the fourth quarter was impressive. Uptick in sales for product groups used in COVID-19 response drove the top line. During the quarter, robust orders for the QIAcuity series of digital polymerase chain reaction or PCR platforms and FDA’s Emergency Use Authorization for the use of saliva samples collected with the NeuMoDx Saliva Collection Kit were also encouraging. Adjusted operating margin expansion and a raised full-year outlook were impressive as well.</p><h3>Downsides</h3><p><b>Reliance on Commercial Relationships:</b> The future level of sales for companion diagnostics depends, to a high degree, on the commercial success of the related medicines for which the tests have been designed. Further, risks remain that the company may be unable to maintain these relationships and its collaborative partners may pursue or develop competing products or technologies, either on their own or in collaboration with others.</p><p><b>Stiff Competition: </b>QIAGEN is facing intensifying competition from firms providing pre-analytical solutions and other products used by QIAGEN’s customers. The markets for some of the company’s products are very competitive and price sensitive as well.</p><h3>Estimate Trend</h3><p>QIAGEN has been witnessing an upward estimate revision trend for 2021. Over the past 90 days, the Zacks Consensus Estimate for its earnings has moved 2% north to $2.50.</p><p>The Zacks Consensus Estimate for first-quarter 2021 revenues is pegged at $555.3 million, suggesting a 49.2% rise from the year-ago reported number.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why You Should Hold on to QIAGEN Stock for Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why You Should Hold on to QIAGEN Stock for Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-19 21:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/heres-why-hold-qiagen-qgen-114811069.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>QIAGEN N.V. QGEN has been gaining on robust segmental growth and a slew of product launches. Its impressive international performance and strong revenues in the fourth quarter of 2020 buoy optimism. ...</p>\n\n<a href=\"https://finance.yahoo.com/news/heres-why-hold-qiagen-qgen-114811069.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ALGN":"艾利科技","QGEN":"快而精医药"},"source_url":"https://finance.yahoo.com/news/heres-why-hold-qiagen-qgen-114811069.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2128616899","content_text":"QIAGEN N.V. QGEN has been gaining on robust segmental growth and a slew of product launches. Its impressive international performance and strong revenues in the fourth quarter of 2020 buoy optimism. However, downsides may result from its reliance on commercial relationships and a stiff competitive landscape.Over the past year, the Zacks Rank #3 (Hold) stock has gained 29.7% versus 1.3% fall of the industry it belongs to and 51.2% rise of the S&P 500.The renowned molecular diagnostics solutions provider has a market capitalization of $12.02 billion. The company projects 17.8% growth for the next five years and expects to maintain strong segmental performance. The company surpassed estimates in two of the trailing four quarters, missed the same in one and broke even in another, the average surprise being 1.41%.Let’s delve deeper.Product Launches: We are upbeat about QIAGEN’s recent product launches. The company, this month, announced the launch of its QIAseq DIRECT SARS-CoV-2 Kit. The kit is a viral genome enrichment and library preparation solution that significantly lessens library turnaround times and plastic use unlike the ARTIC project protocols (primer-based approaches for next-generation sequencing).The company, in March, launched QIAsphere cloud-based solutions to strengthen the scope in digital diagnostics with its syndromic testing platform, QIAstat-Dx. The same month, QIAGEN announced the launch of QIAcube Connect MDx platform for automated sample processing in molecular diagnostic laboratories, which will now be available in the United States and Canada, the European Union, and other markets globally.Collaborations to Add Value: We are optimistic about the collaborations entered into by QIAGEN over the past few months. The company extended its partnership with INOVIO Pharmaceuticals INO in February with a new master collaboration agreement to develop liquid biopsy-based companion diagnostic products based on next-generation sequencing technology to complement INOVIO’s therapies.In November 2020, QIAGEN entered into a strategic collaboration with BioNTech SE with the aim of developing and commercializing a tissue-based therascreen test as a companion diagnostic.Strong Q4 Results: QIAGEN’s robust results in the fourth quarter of 2020 instill optimism. Its revenue growth across all geographies and both operating segments in the fourth quarter was impressive. Uptick in sales for product groups used in COVID-19 response drove the top line. During the quarter, robust orders for the QIAcuity series of digital polymerase chain reaction or PCR platforms and FDA’s Emergency Use Authorization for the use of saliva samples collected with the NeuMoDx Saliva Collection Kit were also encouraging. Adjusted operating margin expansion and a raised full-year outlook were impressive as well.DownsidesReliance on Commercial Relationships: The future level of sales for companion diagnostics depends, to a high degree, on the commercial success of the related medicines for which the tests have been designed. Further, risks remain that the company may be unable to maintain these relationships and its collaborative partners may pursue or develop competing products or technologies, either on their own or in collaboration with others.Stiff Competition: QIAGEN is facing intensifying competition from firms providing pre-analytical solutions and other products used by QIAGEN’s customers. The markets for some of the company’s products are very competitive and price sensitive as well.Estimate TrendQIAGEN has been witnessing an upward estimate revision trend for 2021. Over the past 90 days, the Zacks Consensus Estimate for its earnings has moved 2% north to $2.50.The Zacks Consensus Estimate for first-quarter 2021 revenues is pegged at $555.3 million, suggesting a 49.2% rise from the year-ago reported number.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":373834757,"gmtCreate":1618838009079,"gmtModify":1634290510889,"author":{"id":"3576011893381455","authorId":"3576011893381455","name":"53d72524","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3576011893381455","authorIdStr":"3576011893381455"},"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/373834757","repostId":2128616899,"repostType":4,"repost":{"id":"2128616899","pubTimestamp":1618837751,"share":"https://www.laohu8.com/m/news/2128616899?lang=&edition=full","pubTime":"2021-04-19 21:09","market":"us","language":"en","title":"Here's Why You Should Hold on to QIAGEN Stock for Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2128616899","media":"Zacks","summary":"QIAGEN N.V. QGEN has been gaining on robust segmental growth and a slew of product launches. Its imp","content":"<p><b>QIAGEN N.V.</b> QGEN has been gaining on robust segmental growth and a slew of product launches. Its impressive international performance and strong revenues in the fourth quarter of 2020 buoy optimism. However, downsides may result from its reliance on commercial relationships and a stiff competitive landscape.</p><p>Over the past year, the Zacks Rank #3 (Hold) stock has gained 29.7% versus 1.3% fall of the industry it belongs to and 51.2% rise of the S&amp;P 500.</p><p>The renowned molecular diagnostics solutions provider has a market capitalization of $12.02 billion. The company projects 17.8% growth for the next five years and expects to maintain strong segmental performance. The company surpassed estimates in two of the trailing four quarters, missed the same in <a href=\"https://laohu8.com/S/AONE\">one</a> and broke even in another, the average surprise being 1.41%.</p><p><img src=\"https://s.yimg.com/uu/api/res/1.2/wSmLPh1hcBzgFwpGTezrkw--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/zacks.com/cfa8456f1082b16b66f28fe2c2241e69\" tg-width=\"620\" tg-height=\"377\" referrerpolicy=\"no-referrer\"></p><p>Let’s delve deeper.</p><p><b>Product Launches:</b> We are upbeat about QIAGEN’s recent product launches. The company, this month, announced the launch of its QIAseq DIRECT SARS-CoV-2 Kit. The kit is a viral genome enrichment and library preparation solution that significantly lessens library turnaround times and plastic use unlike the ARTIC project protocols (primer-based approaches for next-generation sequencing).</p><p>The company, in March, launched QIAsphere cloud-based solutions to strengthen the scope in digital diagnostics with its syndromic testing platform, QIAstat-Dx. The same month, QIAGEN announced the launch of QIAcube Connect MDx platform for automated sample processing in molecular diagnostic laboratories, which will now be available in the United States and Canada, the European Union, and other markets globally.</p><p><b>Collaborations to Add Value:</b> We are optimistic about the collaborations entered into by QIAGEN over the past few months. The company extended its partnership with <b>INOVIO Pharmaceuticals</b> INO in February with a new master collaboration agreement to develop liquid biopsy-based companion diagnostic products based on next-generation sequencing technology to complement INOVIO’s therapies.</p><p>In November 2020, QIAGEN entered into a strategic collaboration with <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> with the aim of developing and commercializing a tissue-based therascreen test as a companion diagnostic.</p><p><b>Strong Q4 Results: </b>QIAGEN’s robust results in the fourth quarter of 2020 instill optimism. Its revenue growth across all geographies and both operating segments in the fourth quarter was impressive. Uptick in sales for product groups used in COVID-19 response drove the top line. During the quarter, robust orders for the QIAcuity series of digital polymerase chain reaction or PCR platforms and FDA’s Emergency Use Authorization for the use of saliva samples collected with the NeuMoDx Saliva Collection Kit were also encouraging. Adjusted operating margin expansion and a raised full-year outlook were impressive as well.</p><h3>Downsides</h3><p><b>Reliance on Commercial Relationships:</b> The future level of sales for companion diagnostics depends, to a high degree, on the commercial success of the related medicines for which the tests have been designed. Further, risks remain that the company may be unable to maintain these relationships and its collaborative partners may pursue or develop competing products or technologies, either on their own or in collaboration with others.</p><p><b>Stiff Competition: </b>QIAGEN is facing intensifying competition from firms providing pre-analytical solutions and other products used by QIAGEN’s customers. The markets for some of the company’s products are very competitive and price sensitive as well.</p><h3>Estimate Trend</h3><p>QIAGEN has been witnessing an upward estimate revision trend for 2021. Over the past 90 days, the Zacks Consensus Estimate for its earnings has moved 2% north to $2.50.</p><p>The Zacks Consensus Estimate for first-quarter 2021 revenues is pegged at $555.3 million, suggesting a 49.2% rise from the year-ago reported number.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why You Should Hold on to QIAGEN Stock for Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why You Should Hold on to QIAGEN Stock for Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-19 21:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/heres-why-hold-qiagen-qgen-114811069.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>QIAGEN N.V. QGEN has been gaining on robust segmental growth and a slew of product launches. Its impressive international performance and strong revenues in the fourth quarter of 2020 buoy optimism. ...</p>\n\n<a href=\"https://finance.yahoo.com/news/heres-why-hold-qiagen-qgen-114811069.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ALGN":"艾利科技","QGEN":"快而精医药"},"source_url":"https://finance.yahoo.com/news/heres-why-hold-qiagen-qgen-114811069.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2128616899","content_text":"QIAGEN N.V. QGEN has been gaining on robust segmental growth and a slew of product launches. Its impressive international performance and strong revenues in the fourth quarter of 2020 buoy optimism. However, downsides may result from its reliance on commercial relationships and a stiff competitive landscape.Over the past year, the Zacks Rank #3 (Hold) stock has gained 29.7% versus 1.3% fall of the industry it belongs to and 51.2% rise of the S&P 500.The renowned molecular diagnostics solutions provider has a market capitalization of $12.02 billion. The company projects 17.8% growth for the next five years and expects to maintain strong segmental performance. The company surpassed estimates in two of the trailing four quarters, missed the same in one and broke even in another, the average surprise being 1.41%.Let’s delve deeper.Product Launches: We are upbeat about QIAGEN’s recent product launches. The company, this month, announced the launch of its QIAseq DIRECT SARS-CoV-2 Kit. The kit is a viral genome enrichment and library preparation solution that significantly lessens library turnaround times and plastic use unlike the ARTIC project protocols (primer-based approaches for next-generation sequencing).The company, in March, launched QIAsphere cloud-based solutions to strengthen the scope in digital diagnostics with its syndromic testing platform, QIAstat-Dx. The same month, QIAGEN announced the launch of QIAcube Connect MDx platform for automated sample processing in molecular diagnostic laboratories, which will now be available in the United States and Canada, the European Union, and other markets globally.Collaborations to Add Value: We are optimistic about the collaborations entered into by QIAGEN over the past few months. The company extended its partnership with INOVIO Pharmaceuticals INO in February with a new master collaboration agreement to develop liquid biopsy-based companion diagnostic products based on next-generation sequencing technology to complement INOVIO’s therapies.In November 2020, QIAGEN entered into a strategic collaboration with BioNTech SE with the aim of developing and commercializing a tissue-based therascreen test as a companion diagnostic.Strong Q4 Results: QIAGEN’s robust results in the fourth quarter of 2020 instill optimism. Its revenue growth across all geographies and both operating segments in the fourth quarter was impressive. Uptick in sales for product groups used in COVID-19 response drove the top line. During the quarter, robust orders for the QIAcuity series of digital polymerase chain reaction or PCR platforms and FDA’s Emergency Use Authorization for the use of saliva samples collected with the NeuMoDx Saliva Collection Kit were also encouraging. Adjusted operating margin expansion and a raised full-year outlook were impressive as well.DownsidesReliance on Commercial Relationships: The future level of sales for companion diagnostics depends, to a high degree, on the commercial success of the related medicines for which the tests have been designed. Further, risks remain that the company may be unable to maintain these relationships and its collaborative partners may pursue or develop competing products or technologies, either on their own or in collaboration with others.Stiff Competition: QIAGEN is facing intensifying competition from firms providing pre-analytical solutions and other products used by QIAGEN’s customers. The markets for some of the company’s products are very competitive and price sensitive as well.Estimate TrendQIAGEN has been witnessing an upward estimate revision trend for 2021. Over the past 90 days, the Zacks Consensus Estimate for its earnings has moved 2% north to $2.50.The Zacks Consensus Estimate for first-quarter 2021 revenues is pegged at $555.3 million, suggesting a 49.2% rise from the year-ago reported number.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4080865,"gmtCreate":1618894989873,"gmtModify":1635515723186,"authorId":3576011893381455,"author":{"id":3576011893381455,"idStr":"3576011893381455","authorId":3576011893381455,"name":"53d72524","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":373834757,"type":1,"supId":0,"prevId":0,"content":"lol","text":"lol","html":"lol"}],"langContent":"EN"},{"id":373834149,"gmtCreate":1618837990081,"gmtModify":1634290511233,"author":{"id":"3575416215572570","authorId":"3575416215572570","name":"WilliamTeo","avatar":"https://static.tigerbbs.com/665764fc5f5e89c64f2caa13df0fe1e3","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3575416215572570","authorIdStr":"3575416215572570"},"htmlText":"Why is it","listText":"Why is it","text":"Why is it","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/373834149","repostId":2128616899,"repostType":4,"repost":{"id":"2128616899","pubTimestamp":1618837751,"share":"https://www.laohu8.com/m/news/2128616899?lang=&edition=full","pubTime":"2021-04-19 21:09","market":"us","language":"en","title":"Here's Why You Should Hold on to QIAGEN Stock for Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2128616899","media":"Zacks","summary":"QIAGEN N.V. QGEN has been gaining on robust segmental growth and a slew of product launches. Its imp","content":"<p><b>QIAGEN N.V.</b> QGEN has been gaining on robust segmental growth and a slew of product launches. Its impressive international performance and strong revenues in the fourth quarter of 2020 buoy optimism. However, downsides may result from its reliance on commercial relationships and a stiff competitive landscape.</p><p>Over the past year, the Zacks Rank #3 (Hold) stock has gained 29.7% versus 1.3% fall of the industry it belongs to and 51.2% rise of the S&amp;P 500.</p><p>The renowned molecular diagnostics solutions provider has a market capitalization of $12.02 billion. The company projects 17.8% growth for the next five years and expects to maintain strong segmental performance. The company surpassed estimates in two of the trailing four quarters, missed the same in <a href=\"https://laohu8.com/S/AONE\">one</a> and broke even in another, the average surprise being 1.41%.</p><p><img src=\"https://s.yimg.com/uu/api/res/1.2/wSmLPh1hcBzgFwpGTezrkw--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/zacks.com/cfa8456f1082b16b66f28fe2c2241e69\" tg-width=\"620\" tg-height=\"377\" referrerpolicy=\"no-referrer\"></p><p>Let’s delve deeper.</p><p><b>Product Launches:</b> We are upbeat about QIAGEN’s recent product launches. The company, this month, announced the launch of its QIAseq DIRECT SARS-CoV-2 Kit. The kit is a viral genome enrichment and library preparation solution that significantly lessens library turnaround times and plastic use unlike the ARTIC project protocols (primer-based approaches for next-generation sequencing).</p><p>The company, in March, launched QIAsphere cloud-based solutions to strengthen the scope in digital diagnostics with its syndromic testing platform, QIAstat-Dx. The same month, QIAGEN announced the launch of QIAcube Connect MDx platform for automated sample processing in molecular diagnostic laboratories, which will now be available in the United States and Canada, the European Union, and other markets globally.</p><p><b>Collaborations to Add Value:</b> We are optimistic about the collaborations entered into by QIAGEN over the past few months. The company extended its partnership with <b>INOVIO Pharmaceuticals</b> INO in February with a new master collaboration agreement to develop liquid biopsy-based companion diagnostic products based on next-generation sequencing technology to complement INOVIO’s therapies.</p><p>In November 2020, QIAGEN entered into a strategic collaboration with <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> with the aim of developing and commercializing a tissue-based therascreen test as a companion diagnostic.</p><p><b>Strong Q4 Results: </b>QIAGEN’s robust results in the fourth quarter of 2020 instill optimism. Its revenue growth across all geographies and both operating segments in the fourth quarter was impressive. Uptick in sales for product groups used in COVID-19 response drove the top line. During the quarter, robust orders for the QIAcuity series of digital polymerase chain reaction or PCR platforms and FDA’s Emergency Use Authorization for the use of saliva samples collected with the NeuMoDx Saliva Collection Kit were also encouraging. Adjusted operating margin expansion and a raised full-year outlook were impressive as well.</p><h3>Downsides</h3><p><b>Reliance on Commercial Relationships:</b> The future level of sales for companion diagnostics depends, to a high degree, on the commercial success of the related medicines for which the tests have been designed. Further, risks remain that the company may be unable to maintain these relationships and its collaborative partners may pursue or develop competing products or technologies, either on their own or in collaboration with others.</p><p><b>Stiff Competition: </b>QIAGEN is facing intensifying competition from firms providing pre-analytical solutions and other products used by QIAGEN’s customers. The markets for some of the company’s products are very competitive and price sensitive as well.</p><h3>Estimate Trend</h3><p>QIAGEN has been witnessing an upward estimate revision trend for 2021. Over the past 90 days, the Zacks Consensus Estimate for its earnings has moved 2% north to $2.50.</p><p>The Zacks Consensus Estimate for first-quarter 2021 revenues is pegged at $555.3 million, suggesting a 49.2% rise from the year-ago reported number.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why You Should Hold on to QIAGEN Stock for Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why You Should Hold on to QIAGEN Stock for Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-19 21:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/heres-why-hold-qiagen-qgen-114811069.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>QIAGEN N.V. QGEN has been gaining on robust segmental growth and a slew of product launches. Its impressive international performance and strong revenues in the fourth quarter of 2020 buoy optimism. ...</p>\n\n<a href=\"https://finance.yahoo.com/news/heres-why-hold-qiagen-qgen-114811069.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ALGN":"艾利科技","QGEN":"快而精医药"},"source_url":"https://finance.yahoo.com/news/heres-why-hold-qiagen-qgen-114811069.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2128616899","content_text":"QIAGEN N.V. QGEN has been gaining on robust segmental growth and a slew of product launches. Its impressive international performance and strong revenues in the fourth quarter of 2020 buoy optimism. However, downsides may result from its reliance on commercial relationships and a stiff competitive landscape.Over the past year, the Zacks Rank #3 (Hold) stock has gained 29.7% versus 1.3% fall of the industry it belongs to and 51.2% rise of the S&P 500.The renowned molecular diagnostics solutions provider has a market capitalization of $12.02 billion. The company projects 17.8% growth for the next five years and expects to maintain strong segmental performance. The company surpassed estimates in two of the trailing four quarters, missed the same in one and broke even in another, the average surprise being 1.41%.Let’s delve deeper.Product Launches: We are upbeat about QIAGEN’s recent product launches. The company, this month, announced the launch of its QIAseq DIRECT SARS-CoV-2 Kit. The kit is a viral genome enrichment and library preparation solution that significantly lessens library turnaround times and plastic use unlike the ARTIC project protocols (primer-based approaches for next-generation sequencing).The company, in March, launched QIAsphere cloud-based solutions to strengthen the scope in digital diagnostics with its syndromic testing platform, QIAstat-Dx. The same month, QIAGEN announced the launch of QIAcube Connect MDx platform for automated sample processing in molecular diagnostic laboratories, which will now be available in the United States and Canada, the European Union, and other markets globally.Collaborations to Add Value: We are optimistic about the collaborations entered into by QIAGEN over the past few months. The company extended its partnership with INOVIO Pharmaceuticals INO in February with a new master collaboration agreement to develop liquid biopsy-based companion diagnostic products based on next-generation sequencing technology to complement INOVIO’s therapies.In November 2020, QIAGEN entered into a strategic collaboration with BioNTech SE with the aim of developing and commercializing a tissue-based therascreen test as a companion diagnostic.Strong Q4 Results: QIAGEN’s robust results in the fourth quarter of 2020 instill optimism. Its revenue growth across all geographies and both operating segments in the fourth quarter was impressive. Uptick in sales for product groups used in COVID-19 response drove the top line. During the quarter, robust orders for the QIAcuity series of digital polymerase chain reaction or PCR platforms and FDA’s Emergency Use Authorization for the use of saliva samples collected with the NeuMoDx Saliva Collection Kit were also encouraging. Adjusted operating margin expansion and a raised full-year outlook were impressive as well.DownsidesReliance on Commercial Relationships: The future level of sales for companion diagnostics depends, to a high degree, on the commercial success of the related medicines for which the tests have been designed. Further, risks remain that the company may be unable to maintain these relationships and its collaborative partners may pursue or develop competing products or technologies, either on their own or in collaboration with others.Stiff Competition: QIAGEN is facing intensifying competition from firms providing pre-analytical solutions and other products used by QIAGEN’s customers. The markets for some of the company’s products are very competitive and price sensitive as well.Estimate TrendQIAGEN has been witnessing an upward estimate revision trend for 2021. Over the past 90 days, the Zacks Consensus Estimate for its earnings has moved 2% north to $2.50.The Zacks Consensus Estimate for first-quarter 2021 revenues is pegged at $555.3 million, suggesting a 49.2% rise from the year-ago reported number.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":6,"commentSize":9,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}